Indian Startup Times’ Post

Biotech startup ExSURE PVT. LTD. raises Rs 3-Cr in seed round Founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure focuses on reducing anti-cancer drug’s side effects and toxicity using its patented exosomal drug delivery platform. This platform targets both cancer and cancer stem cells, aiming to minimize chemotherapy’s toxic effects and reduce the likelihood of cancer relapse, ultimately improving the quality of life for cancer patients. #BiotechIndia #CancerTreatment #StartupFunding #Biotech #stemcells

Healthtech startup ErlySign has secured INR 16 Cr (around $1.8 Mn) in Pre-Series A funding round from Ashish Kacholia to further develop its cancer diagnostic solutions👇 The fresh proceeds will be deployed in clinical trials, securing CDSCO (Central Drugs Standard Control Organisation) approvals, and bringing ErlySign’s oral cancer detection kit to market, the startup said in its statement. “It will support research and development, team expansion, and further patent filings,” it added. Founded in 2019 by Shubhendra Singh Thakur and Deovrat Begde, ErlySign or CURO Biosciences develops solutions for early detection of oral cancer. The company also claims to offer India’s first salivary biomarker based test which can identify pre- cancerous conditions much before visible symptoms emerge. To read the in-depth article, click here: https://4-2.co/3PARWVH #news #startup #funding

A new cohort for Tech4Eva - The global Femtech accelerator, was revealed yesterday during the opening ceremony in Bern to around 250 ecosystem players worldwide, virtually and on-site. The 17 selected startups hail from 11 countries and present a broad pallet of solutions around women’s health, with some of the solutions relying on biomarkers like saliva or tears as biomarkers to identify the fertility window more e accurately but also detect diseases like breast cancer. Conditions such as Endometriosis, menopause, fibroid, cervical cancer, pre-term births and more are also being addressed by the cohort. The Swiss startup Herosupport SA is working on a patient-specific immobilization device for radiation oncology, while Calico Biosystems is developing a new drug testing platform for predicting drug efficacy in female patients. Aside from the startup pitches there was a panel comprising Stefan Troller, senior Vice-president at Helbling Technik, Laurent-Dominique Piveteau, CEO of Debiotech, and Chung Looi, CEO of Luna by Ablatus Therapeutics, moderated by Marta V. Gehring, Senior Fellow EPFL Innovation Park. They spoke about different aspects of developing a medtech startup and market entry. Here are a few takeaways: - Create a focus group that includes different players e.g. doctors, patients, nurses, and anyone benefiting from the solution to understand their needs. - Access these key players very early on in the journey for them to understand what you as a startup are doing for them to help you. - Be creative with your solution. -Whether you should make or buy depends: one speaker put it nicely: “If you save on partners, it might take you longer to get in the market” Finally, Jerome Mariethoz, director of health and prevention Groupe Mutuel concluded the event by remarking that Tech4Eva has generally given a stage to brave founders to talk about topics that have been previously considered taboos and to demonstrate what they are doing to tackle these challenges. Society has evolved and change is happening. Thank you, Tech4Eva for inviting us to the opening event. It was a great opportunity to meet and exchange with various players in the Swiss startup ecosystem. Read more about the selected startups in the article: https://lnkd.in/ed2hf7Zh

ExSURE PVT. LTD., a biotech startup founded in 2021, has secured Rs 3 crore in seed funding from Unicorn India Ventures. The funds will be utilized to complete the non-clinical study of its exosome-based drug delivery platform, expand globally with in-house manufactured R&D products, and promote its product offerings, including Exosure, Leucosure, PlantExosure, and Dr. Berries. The company, co-founded by Swastika Paul and Abhishek Dutta, focuses on minimizing the side effects and toxicity of anti-cancer drugs through its patented exosomal drug-delivery platform targeting both cancer and cancer stem cells. EXSURE is a research and development-focused start-up specializing in the development of the next generation of exosome-based cancer therapeutics. They are creating a unique exosome-based chemotherapeutic drug-delivery platform designed to deliver anti-cancer drugs precisely and guidedly into tumor cells and cancer stem cells, minimizing damage to healthy cells. This platform aims to reduce chemotoxicity and lower the risk of cancer recurrence in cancer patients. Their current work involves a breast cancer model, and they have successfully demonstrated the efficiency and effectiveness of their platform in vitro and ex vivo. In vivo validation is ongoing in SCID mice. They have also filed a patent for the formulation being used to create bioengineered drug-loaded targeted exosomes and the methodology behind it. Additionally, EXSURE offers outsourcing services such as cell culture-based assays, exosome-based experiments, and cancer stem cell-based assays. Factacy.ai Congratulates and wishes them well. #innovation #management #digitalmarketing #technology #creativity #futurism #startups

#𝐒𝐮𝐜𝐜𝐞𝐬𝐬𝐒𝐭𝐨𝐫𝐲𝟑 Continuing the series of spotlighting o2h Kickstarter winners and celebrating their success stories, this time we are excited to introduce our latest winner, Palm Therapeutics. Palm Therapeutics, a #USA-based biotech startup in cancer research, is redefining the field with its development of depalmitoylating molecules (DPALMs) that target protein palmitoylation - a novel approach to inhibiting protein function. Their NRas-targeted DPALMs have shown significant in vitro and in vivo efficacy in NRas-driven melanoma models. Palm Tx’s has also been recognised as a 2024 cool company by Connect. Read here - https://lnkd.in/gcYyQ8wu Their innovative work is positively impacting cancer research, and we are proud to support their journey towards finding novel drugs for unmet patient needs and ultimately improving human health! o2h Discovery has supported many early-stage biotech startups through the Kickstarter Award. Our latest edition, 𝐨𝟐𝐡 𝐊𝐢𝐜𝐤𝐬𝐭𝐚𝐫𝐭𝐞𝐫: 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐞 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 is 𝐧𝐨𝐰 𝐥𝐢𝐯𝐞, which is exclusively designed to provide scientific expertise to USA-based biotech startups. If this sounds like a fit for you and you’d like to avail the benefits, below is the link to register your interest and be a part of our success stories. 👉 https://lnkd.in/dAxrjKjn Andrew Rudd Digital Elevator Altitude Marketing Samba Scientific Alchemist Accelerator BioGenerator Ventures BioMotiv #Biotech #Proteomics #DrugDiscovery #Oncology #Innovation #Testimonial #o2hKickstarter #ClientStory #SeedingNewIdeas #CancerResearch

Last quarter was the best fundraising quarter for biotech startups in about two years, hopefully indicating that industry downturn will soon be a thing of the past! Demonstrating this, last week Pathios Therapeutics and Stuart Hughes secured $25M in Series B Financing to advance their unique immunotherapy approach into Clinic 💰 Pathios Therapeutics is a biotech startup whose approach targets the acidic microenvironment. This acidic environment triggers immune cell signaling, via receptors such as GPR65, and ultimately leads to disease progression. Pathios aims to reverse immune alterations by blocking GPR65 signaling which will potentially improve cancer treatment outcomes, especially for patients unresponsive to current therapies. How exciting to see these startups acquiring further funding! 👏 Which companies do you think have the potential to secure funding? #biotech #pathiostherapeutics #immunotherapy #recruiter #researchanddevelopment

BioSapien, a USA- and UAE-based biotech startup, has secured $5.5 million in a pre-Series A funding round led by Global Ventures, with participation from Dara Holdings. The funds will be used to accelerate the development of MediChip, a 3D-printed implant designed to transform cancer treatment by delivering drugs directly to tumors. Noor Sweid of Global Ventures and Khatija A., CEO of BioSapien, highlight the innovative potential of this breakthrough. WAYA https://lnkd.in/ehqShBiz #lifesciences

Cancer focused biotech startup Immuneel Therapeutics Pvt. Ltd. has raised Rs 100 crore from TAIBA Middle East FZ LLC. 💰 This marks the company’s fourth Series A round after raising $11 million in 2019, $1.4 million in 2020, and $15 million in 2022 from investors including F-Prime Capital, Khosla Ventures, and Eight Roads Ventures. The round appears to be ongoing. Immuneel Therapeutics was founded in 2018 by Biocon founder Kiran Mazumdar Shaw, Pulitzer Prize winner Siddhartha Mukherjee, and Kush Parker.  The Bengaluru-based startup aims to make CAR-T cell therapy commercially available to patients in India at affordable prices and is developing the country’s first Phase 2 trial for CD19 CAR-T(IMN-003A) for B cell malignancies (Leukemia & Lymphoma). Read more at the link in our comments section below 👇 #FundingWithYS #Funding #Startups

Seattle Immunotherapy Startup Umoja Biopharma Raises $100M https://lnkd.in/gqJC7qFg Another Seattle-area health startup is raising a big new round of funding. Umoja Biopharma announced a $100 million Series C round that will help the Seattle-based company further develop its CAR T-cell immunotherapy treatments for cancer. Umoja is developing a multi-pronged technology that retools a patient’s immune system in vivo, or within a living organism, to generate cancer-fighting cells inside the body. The company launched in 2019 and is working to commercialize technology developed at Seattle Children’s Research Institute and Purdue University. Its headquarters are in Seattle, and it has a manufacturing operations site in Colorado. The post Seattle Immunotherapy Startup Umoja Biopharma Raises $100M appeared first on Life Science Washington . Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

#DOP Approves Six Startups Under #PRIP Scheme, assures support for further clinical studies (#clinicaltrials) Appreciating the efforts of #NIPER Ahmedabad, Pfizer, and Social Alpha in empowering innovative startups focused on critical health issues like breast cancer, cervical cancer, gastrointestinal cancer, and kidney disease, Dr Arunish Chawla announced that six startup which had secured additional funding under the Promotion of Research and Innovation in #PharmaMedTech (#PRIP) scheme, with DOP approval, and expressed confidence that these Research-Linked Incentive (#RLI) recipients would receive vital support to transition from innovative ideas to real-world solutions. #departmentofpharmaceuticals #dop #RLI #medTech #pharma #prip #indianpharma #research #clinicaltrial